Sultana, Janet
Giorgianni, Francesco
Scondotto, Giulia
Ientile, Valentina
Cananzi, Pasquale
Leoni, Olivia
Addario, Sebastiano Walter Pollina
De Sarro, Giovanbattista
De Francesco, Adele
Puzo, Maria Rosa
Renoux, Christel
Trifirò, Gianluca
Funding for this research was provided by:
Agenzia Italiana del Farmaco, Ministero della Salute (CUP-H56D16000070005)
Article History
First Online: 16 June 2020
Compliance with Ethical Standards
:
: This study was funded by a Grant from the Italian Medicines Agency for the project “Short- and long-term monitoring of the benefit–risk profile of intravitreal use of anti-VEGF drugs through network of clinical and administrative data” (CUP-H56D16000070005) awarded to Gianluca Trifirò.
: An existing data access agreement governing the use of the data used in this study precludes sharing of the data.
: JS, FG, GS, VI, PC, OL, SWPA, GDS, ADF, MPP, and CR have no conflicts of interest that are directly relevant to the content of this article. CR holds a Chercheur-Boursier Junior 2 Salary Award from the Fonds de recherche du Québec – Santé (FRQS). GT has attended advisory boards in the last 5 years, on topics unrelated to this paper, organized by Sandoz, Hospira, Sanofi, Biogen, Ipsen, and Shire and is a consultant for Otsuka. He is principal investigator of observational studies conducted at the University of Messina and funded by several pharmaceutical companies (e.g. Amgen, AstraZeneca, Daiichi Sankyo, IBSA) as well as scientific coordinator of the Master programme “Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real-world data evaluations” at the University of Messina, which is partly funded by several pharmaceutical companies.
: The study abides by the Declaration of Helsinki. The study protocol was notified to the Ethical Committee of the Academic Hospital of Messina, in agreement with the current national legislation, which does not require full ethics approval for observational retrospective studies of a non-interventional nature using anonymized patient data.